Management of Proteinuric CKD with Hypertension in Non-Pregnant Adults
Start an ACE inhibitor or ARB immediately, titrated to maximum tolerated dose, add an SGLT2 inhibitor regardless of diabetes status (if eGFR ≥20), target systolic BP <120 mmHg using standardized measurement, restrict sodium to <2g/day, and add a GLP-1 agonist if glycemic targets aren't met or cardiovascular risk remains high 1, 2.
Medication Selection Algorithm
First-Line Foundation Therapy
ACE Inhibitor or ARB (choose one, never combine)
- Mandatory for all patients with proteinuric CKD and hypertension 1, 2
- Titrate to maximum antihypertensive dose or highest tolerated dose 1
- For severely increased albuminuria (A3): Grade 1B recommendation 2
- For moderately increased albuminuria (A2): Grade 2C recommendation without diabetes, Grade 1B with diabetes 2
- Critical pitfall: Never combine ACEi + ARB + direct renin inhibitor—this is explicitly contraindicated 2
SGLT2 Inhibitor
- Add immediately as foundational therapy if eGFR ≥20 ml/min/1.73 m² 1
- This applies regardless of diabetes status—the 2022 ADA/KDIGO consensus and recent evidence support SGLT2i for proteinuric CKD even without diabetes 1, 3
- Once initiated, continue even if eGFR drops below 20 1
- Provides both kidney protection and cardiovascular benefit 1, 4
Second-Line Add-On Therapy
GLP-1 Receptor Agonist
- Add if glycemic targets not met with metformin and SGLT2i, or if these cannot be used 1
- Also indicated for patients with high cardiovascular risk or ongoing CKD progression 4
- Choose agents with proven cardiovascular benefit 1
- Combination SGLT2i + GLP-1 RA can extend event-free survival by 3-5 years in high-risk patients 5
Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone)
- Add if eGFR ≥25 ml/min/1.73 m², normal potassium, and ACR ≥30 mg/g 1
- Requires type 2 diabetes for current indication 1
- Key monitoring: Implement potassium management strategies (dietary counseling, potassium binders) to avoid discontinuation of beneficial medications 6
Additional Antihypertensive Agents
Most patients require 3-4 agents to reach BP targets 7:
- Calcium channel blocker (dihydropyridine preferred) 7
- Thiazide or thiazide-like diuretic (selection based on eGFR) 7
Blood Pressure Targets
Target systolic BP <120 mmHg when tolerable 2, 5
- This target requires standardized BP measurement (not routine office BP) 2
- Standardized measurement means: automated oscillometric device, patient seated quietly for 5 minutes, proper cuff size, no talking during measurement 2
- Critical caveat: The <120 mmHg target cannot be applied to routine office BP readings—the relationship is too variable to apply correction factors 2
- Supplement with ambulatory or home BP monitoring 2, 6
Lifestyle Modifications
Sodium restriction: <2g sodium/day (equivalent to <5g salt/day) 2, 5
- Grade 2C recommendation but strongly emphasized across all guidelines 2
Physical activity: ≥150 minutes/week of moderate-intensity exercise 2
- Or to level compatible with cardiovascular tolerance 2
Protein restriction: 0.8 g/kg/day 5
Lipid Management
Statin therapy for all patients 1
- Moderate intensity for primary prevention
- High intensity if known ASCVD or multiple risk factors 1
Glucose Management (if diabetic)
Metformin if eGFR ≥30 ml/min/1.73 m² 1
- Reduce to 1000 mg daily if eGFR 30-44, or eGFR 45-59 with high lactic acidosis risk 1
Monitoring Protocol
Annual screening minimum 1:
- eGFR (using validated equations; consider cystatin C for specific populations) 3
- Urine albumin-to-creatinine ratio 1
- Serum potassium (especially with RASi + MRA) 1, 6
- Lipid panel 1
- HbA1c if diabetic 1
More frequent monitoring when:
- Initiating or titrating RASi, SGLT2i, or MRA
- eGFR declining
- Potassium abnormalities present
Evidence Strength Considerations
The convergence of the 2022 ADA/KDIGO consensus 1 and 2021 KDIGO BP guideline 2 provides the strongest framework. The SGLT2i recommendation has been upgraded to Grade 1A for eGFR ≥20 regardless of diabetes status 5, representing the most significant recent shift in practice. The <120 mmHg BP target comes from SPRINT-level evidence but requires strict adherence to standardized measurement protocols 2.
The combination of RASi + SGLT2i forms the non-negotiable foundation for proteinuric CKD with hypertension, with GLP-1 RA and finerenone added based on diabetes status, cardiovascular risk, and disease progression 1, 4.